Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations von Paik, Paul K., Ahn, Linda Su Hyun, Plodkowski, Andrew J., Fan, Pang-Dian, Rudin, Charles M.

Volltext

A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers von Yu, Helena Alexandra, Kim, Rachel, Makhnin, Alex, Ahn, Linda Su Hyun, Ni, Ai, Hayes, Sara A., Young, Robert J., Riely, Gregory J., Kris, Mark G.

Volltext

Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228 von Paik, Paul K., Ahn, Linda Su Hyun, Ginsberg, Michelle S., Plodkowski, Andrew J., Kim, Rachel, Doyle, L. Austin, Rudin, Charles M.

Volltext

Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228 von Paik, Paul K., Qeriqi, Besnik, Ahn, Linda Su Hyun, Ginsberg, Michelle S., Tandon, Nidhi, McFarland, Daniel, Doyle, L. Austin, de Stanchina, Elisa, Rudin, Charles M.

Volltext

A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed PD-L1 IHC low/unknown stage IV squamous cell lung cancers von Paik, Paul K., Srikakulum, Aparajita, Ahn, Linda Su Hyun, Plodkowski, Andrew J., Ng, Kenneth K., McFarland, Daniel, Fiore, John Joseph, Iqbal, Afsheen, Eng, Juliana, Rudin, Charles M.

Volltext